PPT-Biomarkers for personalized therapy in myeloma

Mike Chapman University of Cambridge Department of Haematology Novel agents have improved survival What is a biomarker A characteristic that is objectively measured and evaluated as an indicator of normal biological processes pathogenic processes or pharmacologic responses to a therapeutic intervention. Dr. Andrew Chantry. Senior Clinical Lecturer and Honorary Consultant in . Haematology. University of Sheffield and Sheffield Teaching Hospitals NHS Foundation Trust. UKMF Autumn Educational Day ‘The evolving management of multiple myeloma and related plasma cell disorders’. Dr Matthew Jenner. Consultant Haematologist. Southampton General Hospital . UK Myeloma Forum Autumn Day. 12 November 2014. Introduction. Why define high risk myeloma?. 3. Patient expectations. Outcomes vary widely between different patients. NICE Guideline. Published Feb 2016. Adults with myeloma (and plasma cell leukaemia). Excluded:. Monoclonal . gammopathy. of uncertain significance (MGUS). Amyloidosis. Solitary . plasmacytomas. Included:. James L. Cook, DVM, . PhD. Director, Comparative Orthopaedic Lab & . Mizzou. . BioJoint. Center. cookjl@health.missouri.edu. Osteoarthritis (OA): . Everyone’s Problem. Markets. Canine. 78M companion dogs in US (2015 APPA Survey). Smoldering Myeloma: To Treat or not to Treat Ruben Niesvizky MD Myeloma Center Myelomacenter.org run9001@med.cornell.edu CASE A 47-year-old man is diagnosed with smoldering multiple myeloma . He has Pritesh Patel, MD. OVErview. Disease overview. How I approach initial treatment. Treatment considerations at relapse. ≈96,000. MM patients. How many people are affected by myeloma?. National Cancer Institute Survival Epidemiology and End Results Program SEER Cancer Statistics Review 1975-2012. Available at . Schistosoma mansoni. in . Biomphalaria glabrata. Benson Otarigho. 1,3. ,. , . Leandro Xavier Neves. 2. , . Ananda. Lima Sanson. 2. , . Mofolusho. O. Falade. 1. , William Castro-Borges. 2. 1. Cellular Parasitology . a measurable indicator . that . can . tell . us something about a person’s health or disease . state, for example, . disease (pathological) processes in the body, for example, disease stage. , . biological processes in the body (heart rate, blood pressure, temperature), . Authors: . Kieu Vu, John . Arend. , Nichole . Cadez. , Deb Darnell, Valerie . Somma. , . Randi Rycroft, . Loria. Pollack, . Paran. . Pordell. . Women’s Wellness Connection. BCCP (Triple negative breast cancer). Can we do better?. [Hospital name]. [Date]. What is myeloma?. Cancer of plasma cells. Leads to:. Bone infiltration. - fractures (especially vertebral wedge fractures), hypercalcaemia. - pain. Presented by: . Dr. Puneet Opal . Dr. Hayley McLoughlin. A Virtual Event. March 17-19, 2022. DISCLAIMER. 2022 AAC. A Virtual Event. March 17-19. PRESENTER DISCLOSURES. Dr. Puneet Opal (Northwestern University). H . Nèji. , H . Abid. , A . Mâalej. , S . Haddar. , R . Akrout. *, . M . Ezzeddine. *, S . Baklouti. *, . Z . Mnif. **, J . Mnif. Imaging department . Habib. . Bourguiba. Hospital, . *Rheumatology department . Grace B. Athas, Ph.D. . MLS. Department of pathology, LSUHSC. CLPC Spring seminar series, 2018 . Learning objectives. Review pathophysiology and lab diagnosis of plasma cell neoplasms with a focus on Multiple Myeloma. Developed By Cancer . Information & Support Network. WWW.CISNcancer.org. CISN’s Mission:. To assist in the building of bridges between all of the organizations involved with cancer research..